PRIME MEMBER EXCLUSIVE | 3 Months Free Trial

Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
The Supreme Court: Oral Arguments cover art

The Supreme Court: Oral Arguments

The Supreme Court: Oral Arguments

Written by: Brad Neal
Listen for free

Episodes
  • Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.

    Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
    Apr 29 2026
    Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. | 04/29/26 | Docket #: 24-889 24-889 HIKMA PHARMACEUTICALS V. AMARIN PHARMA, INC. DECISION BELOW: 104 F.4th 1370 CERT. GRANTED 1/16/2026 QUESTION PRESENTED: Congress passed the Hatch-Waxman Act "[t]o facilitate the approval of generic drugs as soon as patents allow." Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S , 566 U.S. 399, 405 (2012). Recognizing that many drugs are approved for both patented and unpatented uses, Congress sought to ensure "that one patented use will not foreclose marketing a generic drug for other unpatented ones." Id . at 415. The statutory mechanism is a "skinny label": Generic drugmakers "carve out" patented uses from their labels, leaving only instructions to use generic drugs for their unpatented uses. See 21 U.S.C. § 355(j)(2)(A)(viii). Congress designed this carve-out mechanism to encourage competition and to protect generic drugmakers from allegations that marketing a generic drug for an unpatented use "actively induces infringement." 35 U.S.C. § 271(b). After all, active inducement requires "clear expression or other affirmative steps taken to foster infringement"-there is no "liability when a defendant merely sells a commercial product suitable for some lawful use." Metro-Goldwyn- Mayer Studios Inc. v. Grokster, Ltd. , 545 U.S. 913, 936-937 & n.11 (2005). The questions presented are: 1. When a generic drug label fully carves out a patented use, are allegations that the generic drugmaker calls its product a "generic version" and cites public information about the branded drug (e.g., sales) enough to plead induced infringement of the patented use? 2. Does a complaint state a claim for induced infringement of a patented method if it does not allege any instruction or other statement by the defendant that encourages, or even mentions, the patented use? LOWER COURT CASE NUMBER: 2023-1169
    Show More Show Less
    Less than 1 minute
  • Mullin, Sec. of Homeland Security v. Doe

    Mullin, Sec. of Homeland Security v. Doe
    Apr 29 2026
    Mullin, Sec. of Homeland Security v. Doe | 04/29/26 | Docket #: 25-1083 25-1083 MULLIN, SEC. DHS V. DOE DECISION BELOW: CONSIDERATION OF THE APPLICATION FOR STAY (25A952) PRESENTED TO JUSTICE SOTOMAYOR AND BY HER REFERRED TO THE COURT IS DEFERRED. CONSIDERATION OF THE APPLICATION FOR STAY (25A999) PRESENTED TO THE CHIEF JUSTICE AND BY HIM REFERRED TO THE COURT IS ALSO DEFERRED. THE APPLICATIONS ARE ALSO TREATED AS PETITIONS FOR A WRIT OF CERTIORARI BEFORE JUDGMENT (25-1083, 25-1084), AND THE PETITIONS ARE GRANTED. THE CASES ARE CONSOLIDATED, AND A TOTAL OF ONE HOUR IS ALLOTTED FOR ORAL ARGUMENT. CERT. GRANTED 3/16/2026 QUESTION PRESENTED: LOWER COURT CASE NUMBER: 25-2995
    Show More Show Less
    Less than 1 minute
  • Cisco Systems v. Doe I

    Cisco Systems v. Doe I
    Apr 28 2026
    Cisco Systems v. Doe I | 04/28/26 | Docket #: 24-856 24-856 CISCO SYSTEMS, INC. V. DOE I DECISION BELOW: 73 F.4th 700 GRANTED LIMITED TO QUESTIONS 1 AND 3 PRESENTED BY THE PETITION. CERT. GRANTED 1/9/2026 QUESTION PRESENTED: 1. Whether the Alien Tort Statute ("ATS"), 28 U.S.C. § 1350, allows a judicially-implied private right of action for aiding and abetting. 2. Whether, if ATS aiding-and-abetting claims are cognizable, mere knowledge rather than purpose suffices to show the requisite mens rea. 3. Whether the Torture Victim Protection Act, 28 U.S.C. § 1350 note, allows a judicially- implied private right of action for aiding and abetting. LOWER COURT CASE NUMBER: 15-16909
    Show More Show Less
    Less than 1 minute
adbl_web_anon_alc_button_suppression_t1
No reviews yet